Therefore, pharmacological targeting of the glucagon-like peptide-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR) which increases insulin release in a glucose-dependent manner and also suppresses appetite leading to weight loss, is an effective strategy against T2D (Graaf et al ., 2016)
15 Meanwhile, chronic inflammation driven by intestinal permeability and autoimmunity, and other factors like processed food16and poor sleep, 17 may suppress thyroid activity
Clinically, the ATTAIN Phase 3 program showed that orforglipron at its highest dose delivered a mean weight loss of 12.4% over 72 weeks, slightly less than the WEGOVY pills 13.6% at 64 weeks, but with a broader, more diverse patient population of over 3,000 participants
Any recent A1c shift
If you're taking it for weight loss, you'll need to meet BMI or comorbidity thresholds
Instead, we encourage smaller, balanced meals with adequate protein and hydration